COVID-19 Alaska Daily Clinical Update, May 27
Alaska DOH sent this bulletin at 05/27/2020 07:36 PM AKDTWednesday, May 27, 2020
Liz Conway Ohlsen, MD
With information from Anne Zink, MD, FACEP, Alaska Chief Medical Officer
|
Hydroxychloroquine and chloroquine were tied to a higher risk of death and increased frequency of heart arrhythmias in COVID-19 in an observational study published last week in the Lancet. The study looked at data from 96,032 patients in 671 hospitals across six continents and included patients started on these treatments within 48 hours of diagnosis, excluding anyone already receiving mechanical ventilation. They controlled for confounding factors such as age, sex, and comorbidities when comparing 14,888 patients who received one of these treatments to the 81,144 patients in the control group. Hydroxychloroquine and chloroquine, with and without a macrolide, were independently associated with a more than tenfold increased risk of new ventricular arrhythmia and overall more than doubled mortality during hospitalization.
These side effects were previously recognized for hydroxychloroquine and chloroquine, as QT lengthening and increased risk of arrhythmias had previously been observed in patients taking the drugs for malaria or autoimmune diseases, so arrhythmogenic effects observed in COVID-19 patients are not surprising. However, since the medicines have not been shown to have any benefit in COVID-19 and are now tied to higher mortality, the World Health Organization paused the use of hydroxychloroquine in their global randomized trial of COVID-19 treatments pending further safety review. Chloroquine was not part of the trial. The WHO is continuing trial use of remdesivir, lopinavir+ritonavir, and lopinavir+ritonavir+interferon beta-1z.
|